Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

Thursday, December 14, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics has commenced a Phase 1 clinical study for AGMB-447, an inhaled small molecule inhibitor targeting ALK5. The trial will assess the drug's safety and efficacy in both healthy individuals and patients suffering from idiopathic pulmonary fibrosis. This marks a significant step in developing new therapies for lung conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-human Phase 1 study initiated.
  • AGMB-447 targets idiopathic pulmonary fibrosis.
  • Potential for innovative treatment in lung diseases.

Full Press Release Details

Ghent, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Frequently Asked Questions

What is AGMB-447?

AGMB-447 is an inhaled small molecule inhibitor targeting ALK5.

Who is conducting the Phase 1 study?

The Phase 1 study is being conducted by Agomab Therapeutics.

What condition is AGMB-447 targeting?

AGMB-447 is targeting idiopathic pulmonary fibrosis (IPF).

When was the first subject dosed?

The first subject was dosed on December 14, 2023.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab AGMB-447 Phase 1 idiopathic pulmonary fibrosis clinical trial
Last updated: Dec 14, 2023

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →